Trial
NCT01048086
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Iowa
Collaborators
Molecular Insight Pharmaceuticals, Inc.
Condition
Neuroblastoma
Intervention
Retinoic Acid
Why stopped
No patients were enrolled because the company that pledged the drug does not yet have it available.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-21